Core Insights - NKGen Biotech, Inc. has appointed Dr. Bruce L. Miller to its Scientific Advisory Board, enhancing its expertise in neurodegenerative diseases, particularly Alzheimer's disease and frontotemporal dementia [1][3]. Company Overview - NKGen Biotech is a clinical-stage biotechnology company focused on developing and commercializing innovative autologous and allogeneic natural killer (NK) cell therapeutics [5]. Leadership and Expertise - Dr. Miller is a distinguished professor at UCSF and has extensive experience in neurodegenerative diseases, having published over 2,000 peer-reviewed articles and authored significant books in the field [2][4]. - His contributions include advancing the understanding of dementia and precision medicine approaches for tauopathies and related conditions [2][4]. Clinical Development - The company is currently executing a Phase 2 clinical trial for its autologous NK cell therapy candidate, troculeucel, aimed at individuals with moderate Alzheimer's disease [3]. - There are plans to explore the use of troculeucel in treating frontotemporal dementia, where early signals have shown promise [3].